Shares of HIMS experienced a dramatic decline today following the unexpected cancellation of its partnership with pharmaceutical giant Novo Nordisk. Investors responded negatively to the news, sending the company's stock price plummeting by more than 20%. The reason for the dissolution of the partnership remains unclear, but industry analysts specu